Lakeview Nursing College names Brassard Interim Dean
Jan. 18—Gina Brassard, of Milford, has been named interim dean of nursing at Lakeview College of Nursing (LCN). She will replace Brittany Lawson, who has returned to teaching full-time at LCN and will become the director of assessment for LCN.
"Dr. Brassard's extensive leadership and deep commitment to nursing education make her an exceptional choice for this critical role. With over thirty-five years in healthcare, she holds a Doctor of Education in Ethical Leadership and a Master of Science in Nursing — Leadership and Management. Her expertise will be instrumental in guiding our nursing program," LCN President Sheila Mingee said.
Brassard's nursing experience spans from medical-surgical, telemetry, and case management for intensive care, medical, surgical, and education units. She has also served as director of nursing for a resident home prior to beginning her role as a faculty member at LCN in 2019.
"I'm excited to learn this new role and to serve the College and its students in a different way," Brassard said.
While at LCN, Brassard served as director of assessment and an associate professor. She has taught several courses at Lakeview, including the following: Adult Health I, Basic Concepts of Pharmacology, Population and Global Health, Leadership and Management, and Concept Synthesis. She has also served as the chair of LCN's curriculum committee and as a member of the admissions committee.
Brassard received the Illinois Nurse Educator Fellowship from the Illinois Board of Higher Education in 2021. She has also received numerous nominations for a DAISY award from the students at LCN for extraordinary compassionate and skillful care as a faculty member.
As a member of the Alpha Alpha Delta Chapter of Sigma Theta Tau, she has served as a board member, vice president, and secretary for this International Honor Society chapter. She is also a member of the Sigma Kappa Chapter for Nursing and a member of the National Society of Leadership and Success through Olivet Nazarene University. Additionally, she is a restorative nurse, an ATI Champion, and holds resident assessment coordinator certification (RAC-CT) and online instructor certification.
Beyond her professional roles, she remains committed to community service. She actively volunteers as a nurse consultant and board member for the ABRA (mentally disabled adults) and is an MDS consultant, demonstrating her belief in giving back and supporting broader healthcare and educational missions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Palantir and TeleTracking Team Up to Enhance Healthcare Operations Using AI-Driven Insights
TeleTracking Technologies, a leading provider of healthcare operations platforms, has teamed up with Palantir Technologies Inc. (NASDAQ:PLTR), known for its expertise in artificial intelligence systems. The two companies have formed a strategic partnership with the goal of transforming how hospitals and health systems make operational decisions, ultimately creating long-term value for healthcare providers around the world. The collaboration will integrate TeleTracking's Operations IQ platform with Palantir Technologies Inc. (NASDAQ:PLTR)'s AI-driven tools, including Foundry and AIP. This combined solution is expected to equip hospitals with near real-time, actionable insights to improve staffing efficiency, speed up decision-making, and ensure that patient needs remain the top priority. As healthcare systems continue to face increasing demands to enhance capacity and coordination without expanding their physical footprint, this partnership represents a significant step forward. By bringing together TeleTracking's operational strengths and Palantir Technologies Inc. (NASDAQ:PLTR)'s cutting-edge technology, the two aim to usher in a new era of intelligent, scalable, and efficient healthcare delivery. Alex Karp, CEO at Palantir Technologies Inc. (NASDAQ:PLTR) made the following comment: 'This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of—where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care.' Palantir Technologies Inc. (NASDAQ:PLTR) is an American publicly traded company that focuses on developing software platforms designed for analyzing large volumes of data. While we acknowledge the potential of PLTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS). 9.1 point average rVCSS improvement among the responder cohort. A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS). Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size. Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym). Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation View the original press release on ACCESS Newswire
Forbes
a day ago
- Forbes
Food Safety Depends On Every Link In The Supply Chain
Colorful fish and vegetables can be purchased at a public market. For communities to be nourished, their food supply must be safe to eat. This sounds obvious, but it's worth repeating, because every year, about 1 in 10 people worldwide (or about 600 million people) become sick from contaminated food, and 420,000 lose their lives. About 125,000 of those deaths annually are children under 5 years old—a disproportionate tragedy that comes at the expense of our future. And in low- and mid-income countries, US$110 billion is lost every year in productivity and medical expenses resulting from unsafe food, per World Health Organization (WHO) data. Addressing food safety is truly crucial not just to our lives but to our livelihoods, our economic success, and the well-being of every aspect of the food system. World Food Safety Day, on June 7, is a perfect opportunity for everyone around the globe to recommit to ensuring a safe food supply for all. 'Food safety is not just about preventing harm,' says Markus Lipp, Senior Food Safety Officer at the UN Food and Agriculture Organization. 'It is about creating confidence and trust in the food we eat, in the systems that protect us, that protect food safety and in the institutions that serve the public good for safe food.' So how do we ensure the future of food is safe? First: Food safety is not isolated—every link along the food chain must prioritize safety. Food safety begins on fields and farms, with healthy soils and positive growing practices, and continues through processing, transportation, cooking, and serving. This whole-system approach can be truly transformative. In fact, many of the 200+ diseases 'that we know can be carried by food are preventable and sometimes even eradicable,' says Luz María De Regil, Director of the Department of Nutrition and Food Safety at WHO. Second: We can't just respond to challenges that currently exist; we have to be prepared to face unprecedented and complex challenges to food safety as the climate crisis worsens. According to the WHO, the changing climate will affect the persistence and occurrence of bacteria, viruses, parasites, harmful algae, and fungi—and the vectors that spread them. 'We're going to have emerging pathogens coming in, especially given that the climate is changing…microbes like hot, humid, wet environments,' said Barbara Kowalcyk, an Associate Professor at the Milken Institute School of Public Health. Third: Perhaps most urgently, we need to champion evidence-based policymaking and global cooperation. This year's World Food Safety Day highlights this, focusing particularly on the 'essential role of science in ensuring food safety and enabling informed decision-making.' Now more than ever, we need to devote more resources to scientific progress, international collaboration, and solid regulatory frameworks—not less. But recent cuts to research funding and staff in the United States by the Trump-Vance Administration, including in food safety inspection labs, are having concerning ripple effects across the globe. Foodborne illness outbreaks could become harder to detect and contain, leading to more people in more widespread areas getting sick, experts warn. In addition, the dismantling of the U. S. Agency for international Development (USAID) shuttered several Feed the Future Innovation Labs, which brought university research to countries including Kenya, Nepal, Nigeria, Bangladesh, Ethiopia, Ghana, and Guatemala to design and implement food safety interventions in poultry production, post-harvest crop storage, farmers markets, households, and more. So this World Food Safety Day, WHO's calls to action encourage all of us—policymakers, business leaders, and eaters—to step up. Communities can find ways to apply the WHO's Global Strategy for Food Safety 2022-2030, to ensure that all people, everywhere, consume safe and healthy food. And initiatives like the GAIN's EatSafe program and the Codex Alimentarius Commission, which aims to standardize evidence-based food safety protocols in ways that respect local culture, offer models to learn from. I often think of something Abdou Tenkouano told me last year. At that time he was the Executive Director of CORAF, an organization in West and Central Africa that uses agriculture to build community resilience, and now he's Director General at icipe, which uses insect science to tackle food security, health, and environmental challenges in Africa. 'This is a global village,' he said. 'We are all interconnected, interdependent, interlinked.' And when it comes to food, we all have a responsibility to keep one another safe.
